About My Risk
My Risk is a company based in United States founded in 2021. It operates as a B2C. My Risk offers products and services including Risk Calculator. My Risk operates in a competitive market with competitors including Resilience, Aware, PinkDetect, DearMamma and OWise, among others.
- Headquarter United States
- SectorsHealthcare
- Website myriskbreastcancer.com
- Social YouTube
- Legal Name Red Canvas Llc
Products & Services of My Risk
My Risk offers a comprehensive portfolio of products and services, including Risk Calculator.
Calculates personalized breast cancer risk for early screening recommendations.
Apps and channels of My Risk
My Risk publishes 2 mobile apps with over 1K+ downloads; its YouTube channel Florida Breast Cancer Foundation has 8 subscribers and 8 videos.
Videos from My Risk
The most watched videos on My Risk's YouTube channel, Florida Breast Cancer Foundation (8 subscribers). Click a video to play it here.
More on Florida Breast Cancer Foundation.
Competitors of My Risk
My Risk operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Resilience, Aware, PinkDetect, DearMamma and OWise, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| resilience.care | 2021 | Paris, France | $77M | – | A digital solution is provided for remote oncology monitoring. | |
| xaware.net | 1999 | Colorado Springs, United States | $7.4M | – | Aware is focused on providing AI-driven design solutions and content. | |
| pinkdetect.com | 2023 | Toronto, Canada | – | – | App provides breast cancer risk assessments and self-exam guidance for women. | |
| dearmamma.org | 2006 | Affoltern Am Albis, Switzerland | – | – | Provides an app with tools for managing breast cancer. | |
| owise.uk | 2012 | London, United Kingdom | – | – | Personalized cancer support app is provided for patient wellbeing tracking. | |
| breastcare.app | 2020 | Wurzburg, Germany | – | – | Offers a platform with a breast cancer app for early detection and information. | |
| mylumps.com | 2021 | Tampa, United States | – | – | Mobile app for tracking self-breast exams, annotating findings, and sharing with doctors. | |
| feelforyourlife.com | 2018 | Sacramento, United States | – | – | Provides app for breast health reminders, tracking, resources, and advocacy support. |
Detailed competitors of My Risk
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to My Risk
10 companies that operate in the same segment as My Risk (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about My Risk
My Risk was founded in 2021.
My Risk is headquartered in United States.
This platform offers a risk calculator via app and website to assess individual breast cancer risk based on factors like age and family history. It provides statistics, educational content, and screening recommendations from organizations like the American College of Radiology. Targeting women, men, and transgender individuals, it promotes early detection in the United States. Sponsored by Florida Breast Cancer Foundation, it aims to empower users with personalized health insights.
My Risk's top competitors include Resilience, OWise and Aware.
My Risk offers Risk Calculator.
My Risk operates through Red Canvas Llc.
Yes. My Risk publishes My Risk Breast Cancer and 1 more app, with over 1,000 downloads.